ABSTRACT. The cytoskeletal network of cells is postulated to play a role in the signal transduction pathways of growth promoting stimuli. Weshow here that cytoskeletal active drugs modulate the mitogenic signal transduction pathway of the tumor promoter TPA in 3T3-L1 cells. Compounds which act on microtubules (vinblastine sulfate) and micro filaments (cytochalasin B) have opposite effects on DNAsynthesis. Vinblastine sulfate leads to stimulation, whereas cytochalasin B causes potent inhibition of DNAsynthesis in response to TPA. These drugs are cell cycle specific and apparently exert their regulatory action distal to activation of protein kinase C by TPA. The expression of four genes necessary for DNAsynthesis in response to tumor promoters was examined: two nuclear proto-oncogenes (c-myc and c-fos), a transcription factor (c-jun/AP-1) and a key enzyme involved in polyamine synthesis (ornithine decarboxylase). c-jun mRNA levels are not modulated during the action of cytoskeletal disrupting drugs on TPA-mediated mitogenesis, whereas c-myc and c-fos mRNA levels are similarly enhanced. Expression of ornithine decarboxylase mRNA and protein is increased by vinblastine sulfate but decreased by cytochalasin B in TPA treated cells. These data indicate that changes in cytoskeletal organization may play a role in regulating the levels of an enzyme critical for DNAsynthesis.
can stimulate the entry of cells into the DNAsynthetic phase of the cell cycle (9). In addition, microtubule disrupting drugs can also enhance the effect of growth factors on stimulation of DNAsynthesis (19, 21, 36, 43, 52, 55) . In contrast, agents which stabilize the cytoskeletal network, such as taxol, or disrupt the micro filament network, such as the cytochalasins, block the induction of DNAsynthesis in response to growth factors (16, 35, 40) . Thus, perturbation of the cytoskeleton can have both inhibitory and stimulatory effects upon signal transduction by growth factors depending on the particular pathway utilized.
Several growth factors have been shownto exert their * To whomcorrespondence should be addressed and current address: Department of Molecular Pharmacology, Stan ford University School of Medicine, Stan ford, CA94305-5332.
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mitogenic effect through activation of phospholipase C leading to turnover of membranephospholipids and formation of diacylglycerol, a potent activator of protein kinase C (PKC). PKC is a key intracellular enzyme found in a variety of cell types. Tumorpromoters, such as the phorbol ester 12-O-tetradecanoyl-phorbol-1 3-acetate (TPA), bind directly to PKC resulting in activation of the enzyme (10, 41) . Tumorpromoters serve as an important tool for dissecting the PKCpathway and its role in cellular proliferation.
Someattempts have been made to decipher the specific biochemical and molecular events involved in mediating the influence of the cytoskeleton on gene expression and cell proliferation (7, 15, 46, 57) . To define the role of the cytoskeleton in mitogenic signal transduction in the PKCpathway we have studied the effect of cytoskeletal active drugs on TPA-stimulated mitogenesis in mouse 3T3-L1 cells at both a biochemical and a molecular level. Vinblastine sulfate leads to stimulation, whereas cytochalasin B causes potent inhibition of DNAsynthesis in response to TPA. These knowncytoskeletal disrupting drugs apparently exert their regulatory action distal to activation of protein kinase C by TPA. Analysis of the expression of four genes necessary for DNAsynthesis in response to tumor promoters (c-myc, c-fos, c-jun and ornithine decarboxylase) sug-gest that changes in ornithine decarboxylase levels may serve as a mechanismfor modulating DNAsynthesis in response to cytoskeletal active drugs in the PKCpathway. Ourresults are consistent with a role for the cytoskeleton in the signal transduction pathways of particular growth factors.
MATERIALS AND METHODS
Materials. Cytochalasin B (CB), vinblastine sulfate (VS) and TPA were purchased from Sigma Chemical Co., St.
Louis, MO. All cell culture supplies were purchased from GIBCO, Grand Island, NY.
Meth ods. Cell culture and measurement ofDNAsynthesis. 3T3-L1 fibroblasts (American Tissue Type Collection, Rockville, MD)
were grown in DME containing 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100^g/ml streptomycin in a humidified 5% CO2 environment at 37°C. In order to obtain quiescent cells, con fluent cultures were fed with media containing 5%FBS and maintained for 5-6 days before use in experiments. The various compoundsto be tested were added directly to the conditioned media at time 0 unless otherwise indicated. All compounds were dissolved in H2O except TPAand CB which were dissolved in DMSO.Triplicate cultures in 12-well culture plates were labeled with 1 fid/ml [3H]-thymidine (60-90 Ci/mmol; ICN, Irvine, CA) from 21-22 hours after stimulation. The cultures were placed on ice, washed twice with cold Dulbecco's PBS and fixed with 5% TCA overnight. The cultures were washed twice with 5%TCAand the cells solubilized in 0.5 ml of 1 N NaOHfor several hours at 37°C. After neutralizing with 6 N HC1, TCAinsoluble radioactivity wasmeasured by scintillation counting. pH]-Phorbol dibutyrate (PDBu) binding. After treatment with TPA, CB and/or VS for 24 hours at 37°C, con fluent 3T3-L1 cultures (5 days conditioned in DMEcontaining 5% FBS in 35 mmdishes) were placed on ice and washed twice with DMEcontaining 20 mMHEPES, pH 7.4. Cultures were covered with 1 ml DME-HEPEScontaining 9.6ng [3H]-PDBu (0.2 fid; New England Nuclear, Boston, MA) and incubated at 23°C for 60 minutes (50). To terminate the reactions, the dishes were placed on ice. The cells were washed three times with 2 ml of ice-cold DME-HEPES,and then dissolved in 1 N NaOH.After neutralizing with 6 N HC1, the radioactivity was measured by scintillation counting. Nonspecific binding was measured in the presence of 2.5 fig ofunlabeled PDBu and subtracted from total binding to obtain specific binding. Cellfractionation.
Con fluent cultures (6 days conditioned in DMEcontaining 5% FBS in 150 mmdishes) were treated with TPA, CB and/or VS for 5 minutes at 37°C, washed twice with 5ml PBS, scraped into 5 ml of PBS containing 1 mM PMSF, washed with 5 ml of 0.25 M sucrose containing 1 mM PMSFand stored at -70°C. The frozen cell pellets were lysed in 0.2ml SEAT buffer (0.25 M sucrose, 1 mMEDTA, 10mM acetic acid, 10 mMtriethanolamine, pH 7.4) containing 0.5 mMEGTAby repeated pipetting of the suspension. The precipitate after centrifugation at 1,000 rpm for 6 min (nuclear fraction) was washed with 1 ml SEATbuffer and suspended in 100(A of 20mMpotassium phosphate (pH7.5), 0.5 mM EGTA, 0.5 mMEDTA, 10% glycerol, 10 mM2-mercaptoethanol (buffer A). Growth arrested cultures were treated with the various drugs either singly or in combination. After the indicated time, the dishes were washed twice with methionine-free DME,2 ml of methionine-free DMEcontaining 110 /iCi of Trans35S-label (ICN, 1059 Ci/mmole) added and incubated for 30 minutes at 37°C, 5% CO2. The medium was aspirated and the dishes were washed 3 times with 2ml of ice cold PBS containing 1 mMPMSF.The cells were frozen and thawed in 25 mMTrisHCl pH7. . After the mixture was incubated with rotation for 5 hours at room temperature, the immunoprecipitate was pelleted at 14,000 x g for 2 minutes and washed 3 times on ice with 1 ml of 25 mMTris-HC1 pH7.5, 0.1% SDS, 0A% Triton X-100, 1 mM DTT, 2 mMEDTAand 5 mML-methionine. The washed immunoprecipitate was resuspended in 50 [A of 2 x Laemmli's sample buffer (33), heated at 95°C for 5 minutes and centrifuged. The supernatant was electrophoresed on 10% SDS-2Murea-polyacrylamide slab gels (33). The gel was fluorographed using 1 M sodium salicylate (12) . The dried gel was exposed to Konica type A film and scanned with a Betascope 603 bot analyzer (Betagen, Waltham, MA).
RESULTS
To define the role of the cytoskeleton in the stimulation of DNAsynthesis by the protein kinase C pathway, we treated 3T3-L1 fibroblasts with VS and CB which disrupt microtubules and micro filaments, respectively. 3T3-L1 cells can be growth-arrested in G0/Gi of the cell cycle either by serum starvation or by density arrest.
Upon addition of purified growth factors or serum, these cells can be stimulated to enter Gi and proceed through the cell cycle leading to DNAsynthesis and cell division. The protein kinase C activator TPAwas added at time 0 and VS or CB added at various times after addition of TPA. Both VS and CBcaused pronounced effects on cell shape. Cells were pulsed for 1 hour with [3H]-thymidine at 21 hours after TPAstimulation to measure incorporation into DNAas determined by TCAinsoluble counts. Initial experiments indicated that the peak of TPA-induced DNAsynthesis occurs at approximately 20 hours. As shown in Figs, la and b, these drugs exert their effects within very different times frames. Fig. la depicts the results from a representative experiment indicating that VS exerts its maximumstimulatory effect only whenadded concomitantly with TPA. As early as 30 minutes later the level of augmentation is lower. In fact, when VS is added 8 to 12 hours after TPAstimulation the levels of DNAsynthesis are inhibited relative to TPAaddition alone. In three separate experiments, the addition of VS at time 0 consistently gave maximumenhancement of TPA-stimulated DNA synthesis although the exact magnitude varied approximately 2 to 6 fold. VS treatment did not alter the timing of the peak of TPA-induced DNAsynthesis (data not shown DNAsynthesis occurs distal to PKC binding. In con fluent growth-arrested 3T3-L1 cells, the addition of TPAcauses an activation and translocation of protein kinase C within minutes. Twominutes after stimulation by TPAthe enzyme translocates from an inactive cytosolic fraction to an active tightly bound membrane fraction (51). This translocation has been shown to be necessary for the activation of the enzyme (32). The subsequent series of events in the mitogenic signal transduction pathway are for the most part unknown. To examine if the cytoskeletal disrupting drugs VSand CB affect the ability of the enzyme to undergo this acti- TPA-treated cells the membraneand nuclear fractions have increased in activity with the membraneform predominating. The cellular distribution of PKC is no different when cells are treated with TPAtogether with VS or CB. When PKC is activated by TPA in the presence of these two drugs, the enzyme is apparently able to undergo its characteristic translocation. Thus, these drugs cause their characteristic stimulatory or inhibitory effect after the translocation of PKC. Since the exact mechanism by which activation of PKCby tumor promoters leads to stimulation of DNA synthesis is unknown, the expression of a numberof genes shown to be necessary for DNAsynthesis was examined. These included c-myc and c-fos, two cellular proto-oncogenes whose expression is induced very early in response to serum and growth factors (8, 23, 30, 54) . Con fluent growth-arrested 3T3-L1 cultures were treated with TPAalone or in conjunction with different concentrations of VS and CB. RNAwas harvested 1 hour after stimulation and analyzed for steady state levels of c-fos and c-myc. The results in Fig. 2 demonstrate that, as for other growth-promoting compounds, TPA treatment causes an induction of both c-fos (Fig. 2a, lanes 2-5) and c-myc (Fig. 2b, lanes 2-5) as compared to control DMSOtreated cells (lane 1). VStreatment alone does not induce the steady state levels of c-fos mRNA (Fig.   2a , lane 6) but does lead to a small increase in c-myc mRNAlevels (Fig. 2b, lane 6) ; CB alone had no effect Con fluent cultures of quiescent 3T3-L1 cells were treated with DMSO(0.1%), TPA (lOOng/ml), VS (0.2//M), CB (1 pM) or combinations of these drugs for 5 minutes at 37°C. Cellular fractions were prepared and protein kinase C activity was measured as described in Methods. Numbers in parentheses indicate protein kinase C activity relative to DMSO control. on either transcript (lane 9). A 2 to 3 fold increase in both c-fos and c-myc mRNA levels were observed when cells were treated with TPAand different concentrations of VS (lanes 3-5) or CB (lanes 7, 8) . Since these drugs have opposite effects on TPA-induced DNAsynthesis, but both cause comparable increases in c-fos and c-myc mRNAlevels, this implies that changes in the levels of mRNA for the proto-oncogenes c-fos and c-myc are not responsible for the modulation of TPA-induced DNAsynthesis by cytoskeletal active drugs. A number of TPAresponsive genes contain the consensus sequence for binding of the transcription factor AP-1 (4, 14, 34) . The product of the proto-oncogene cjun has been shown to be homologous to the AP-1 protein family (3, 6). Changes in c-yw/z/AP-l mRNAand protein occur as a result of TPAstimulation of cells due to transcriptional and translational alterations (3). Because c-jun/AP-l appears to be intimately involved in the signal transduction pathway of TPA, we examined its levels during VS and CB treatment of TPA-stimulated cells. Northern analysis (Fig. 3) arrested 3T3-L1 cultures were treated with TPA, TPA +VS or TPA+CB.RNAwas extracted from the cells after 6 hours of stimulation when peak levels of ODC transcripts are observed (data not shown). Northern analysis (Fig. 4) indicates that TPA+VS treatment (lane 3) results in approximately 2-fold higher levels of ODCmRNAthan TPA alone (lane 2), whereas TPA+ CB treatment (lane 5) results in a marked reduction in ODClevels. Similar changes in response to drug treatment were observed at the protein level (Fig. 5) . Immunoprecipitation of radioactively pulse labelled cultures with an antiserum to ODC(29) was used to study newly synthesized ODCprotein in response to drug treatment. TPAcaused a 5.3 fold increase in newly synthesized ODCprotein which was augmented by VS to a 12.7 fold increase relative to control. The approximately 2-fold induction by TPA+VSover TPAalone is similar to the magnitude of induction observed at the mRNA level for these drugs. Addition of CB to TPA treated cultures largely blocked the observed increase in protein synthesis. Therefore, the mechanismfor the modulationof TPA-mediated DNAsynthesis by these cytoskeletal disrupting drugs may be due in part to altered levels of ODCprotein synthesis.
DISCUSSION
Tumor promoters such as TPAact as potent mitogens for cultured cells. These compoundsdirectly activate the intracellular enzymePKCleading to a series of uncharacterized steps that culminate in DNAsynthesis and cell division. Wehave shownthat knowncytoskeletal disrupting drugs, at concentrations which block cell division in other systems, cause significant changes in TPA-stimulated mitogenesis. VS, an inhibitor of microtubular assembly, acts to stimulate mitogenesis, while cytochalasin B, a micro filament inhibitor, leads to inhibition of TPA-stimulated mitogenesis. VSwas maximally stimulatory only when added concomitantly with TPA. In contrast, the addition of CB during the first 8 hours after TPAstimulation completely inhibited TPAmediated mitogenesis. The differences in the kinetics of these two drugs suggests that different processes in Gi are affected by the drug-induced changes in cytoskeletal Another proto-oncogene, c-jun/AP-1 , appearsto be intimatelyinvolvedin the signaltransductionpathway of TPA. Induction of mRNA for the transcriptionfactor AP-1is known to be averyearly eventin Giandpresumably involvedin the subsequent expressionof genes necessaryfor mediatingthe effect of growth-promoting Shimizu and N. Shimizu, in preparation). The lack of synergism between TPAand VS suggests that these compounds affect c-jun/AP-1 mRNA accumulation by a similar pathway. ODCis the rate-limiting enzyme for the production of polyamines which are ultimately necessary for DNA synthesis. ODClevels are highly regulated in response to growth-promoting stimuli by both transcriptional (20, 22, 28, 31, 38) and post-translational (26, 37, 49) control as well as by the stability of the enzyme (25, 27, 37) . The expression of ODCwas decreased by CB but increased by VS in TPA-treated cells at both the mRNA and protein level. The mechanisms responsible for changes in ODCmRNAare unknown. Changes in ornithine decarboxylase mRNA and ultimately protein may serve as a mechanismby which these drugs modulate the stimulation of DNAsynthesis by TPA. Additionally the observed inhibition of DNAsynthesis at early times after CB treatment may be due to the impaired activation of preexisting ODCmolecules which could require an intact cytoskeleton as observed in T cells (48). In summary,our studies suggest that cytoskeletal active drugs affect the mitogenic signal transduction pathway of the intracellular enzyme PKCwhich is intimately involved in cellular proliferation. Microtubule-disrupting drugs stimulate TPA-mediated mitogenesis in mouse fibroblasts, whereas micro filament-disrupting drugs have an inhibitory action. This modulation of DNAsynthesis occurs distal to activation of PKCand appears to involve ornithine decarboxylase, an enzyme integral to DNAsynthesis. These data support a role for the cytoskeleton in growth control.
